Be part of the knowledge.

ReachMD is even better when
you join the community!
Registration is free and easy.

Register Now

Highlights from ESMO 2016: The Continued Rise of Anti-PD-1 Therapy in the Treatment of NSCLC

Lung cancer is the leading cause of cancer-associated mortality, with almost 225,000 new cases and over 158,000 deaths estimated in 2016 in the Uni...

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Lung cancer is the leading cause of cancer-associated mortality, with almost 225,000 new cases and over 158,000 deaths estimated in 2016 in the United States alone. Non-small cell lung cancer (NSCLC) represents approximately 85% of those cases. Join us as Dr. Birnholz and Dr. Kim review the data presented at the 2016 annual ESMO conference and discuss the continued rise of anti-PD-1 therapy in the treatment of NSCLC. 

    Since the recording of this interview, pembrolizumab was approved by the FDA on October 24, 2016 for use in Non-small Cell Lung Cancer.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.


    Edward S. Kim, MD, FACP
    Chair, Solid Tumor Oncology and Investigational Therapeutics
    Donald S. Kim Distinguished Chair for Cancer Research
    Levine Cancer Institute
    Carolinas HealthCare System
    Charlotte, NC

    • Dr. Kim receives consulting fees from AstraZeneca, Boehringer-Ingelheim, Celgene, and Eli Lilly.


    • Sean T. Barrett has nothing to disclose.
    • Barry A. Fiedel, PhD has nothing to disclose.
    • Kia K. Gray, MPH has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Jennifer Spear Smith, PhD has nothing to disclose.
  • Learning Objectives

    At the conclusion of this CME activity, participants managing patients with non-small cell lung cancer (NSCLC) will be better able to:

    • Understand recent developments related to use of checkpoint inhibitors for NSCLC in both second- and first-line settings.
    • Evaluate the use of biomarkers in identifying patients most likely to benefit from a particular immunotherapy strategy.
    • Appreciate the possible future and broader uses of immunotherapy in combination and/or sequential regimens for patients with NSCLC.
  • Target Audience

    This activity is designed to meet the educational needs of oncologists.

  • Accreditation and Credit Designation Statements

    The Omnia-Prova Education Collaborative, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs educational activities based on evidence-based medicine, needs and gaps analyses, learner feedback, and more. Its mission is to serve as an innovative and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

    Prova Education

  • Commercial Support

    This activity is supported by an independent educational grant from Merck.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience."

Facebook Comments

You must be in to display playlists.

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.